摘要
目的探讨紫杉醇联合顺铂腹腔热灌注在晚期卵巢癌患者中的应用及对生存期的影响。方法选取2010年1月~2011年1月我院收治的晚期卵巢癌患者86例,随机分为两组,对照组应用紫杉醇联合顺铂静脉滴注治疗,研究组应用紫杉醇联合顺铂腹腔热灌注治疗,对比两组的治疗效果以及生存期。结果研究组患者治疗有效率为79.06%,显著优于对照组的51.16%(P<0.05);治疗前两组患者的CA125水平无明显差异(P>0.05),治疗后两组患者CA125水平均显著下降,且研究组明显低于对照组(P<0.05);研究组患者的不良反应发生率为25.58%,显著低于对照组的32.56%(P<0.05);研究组中位生存期为(57.1±6.9)个月,对照组为(44.2±5.8)个月,差异无统计学意义(P>0.05);研究组无进展生存期为(25.4±4.6)个月、1年生存率为88.37%、2年生存率为67.44%,均明显高于对照组的(18.6±3.5)个月、62.79%和51.16%,差异均有统计学意义(P<0.05)。结论晚期卵巢癌患者应用紫杉醇联合顺铂腹腔灌注给药,能够显著改善近期疗效,降低不良反应发生风险,延长患者生存期。
Objective To investigate the effect of paclitaxel combined with cisplatin on the survival of patients with advanced ovarian can- cer by peritoneal perfusion. Methods 86 patients with advanced ovarian cancer were collected and divided into control and research groups randomly from January 2010 to January 2012 in our hospital, 43 cases for each group. Patients in control group were given intravenous paelit- axel plus cisplatin, while patients in research group were given paclitaxel plus cisplatin by peritoneal peffusion. Compare treatment effect and survival of the two groups. Results The effective rate of research group was 79.06%, and it was significantly higher than that of control group （51.16%） （P 〈0.05）. The CA125 levels of both groups showed no significant differences before treatment （P 〉0.05）. After treatment, the CA 125 levels of both groups decreased, whereas that of the research group was significantly lower than that of the control group （P〈0.05）. The adverse reaction rate of research group was 25.58%, which was significantly lower than that of control group （32.56%） （P〈 0.05）. The median survival time was （57.1 ± 6.9） months in the research group, and was （44.2± 5.8） months in the control group; there was no significant difference be- tween the two groups （P〉0.05）. However, the progression free survival of the research group （25.4 ± 4,6 months） was significantly longer that of the control group （18.6 ± 3.5 months） （P〈 0.05）. The 1-year survival rate （88.37%） and 2-year survival rate （67.44%） of research group were also significantly higher than those of the control group （respectively 62.79% and 51.16%）, and the differences were statistically significant （P〈 0.05）. Conclusion Paclitaxel combined with cisplatin by intraperitoneal perfusion for treatment of patients with advanced ovarian cancer can significantly improve the short-term efficacy, reduce the risk of adverse reactions and prolong the survival time of patients.
作者
王海燕
许芙蓉
王红
胡昌华
蒋红梅
WANG Haiyan XU Furong WANG Hong HU Changhua JIANG Hongmei(Department of Obstetrics and Gynecology, Wuhan Red Cross Hospital, Wuhan, Hubei, 430015, China Department of Obstet- rics and Gynecology,Wuhan Maternal and Child Health Care Hospital, Wuhan, Hubei, 430015, China Department of Obstet- rics and Gynecology,Wuhan Hanyang Hospital, Wuhan, Hubei, 430056, China)
出处
《肿瘤药学》
CAS
2017年第3期315-318,349,共5页
Anti-Tumor Pharmacy
关键词
紫杉醇
顺铂
腹腔灌注
晚期卵巢癌
生存期
cisplatin
intraperitoneal perfusion
advanced ovarian cancer
survival time
